Balazs Halmos
@BalazsHalmosMD
Thoracic/precision oncology 🇭🇺🇺🇸
Learning quick you are GIFted young Jedi Mihaela!
The one & only Yoda of memes @BalazsHalmosMD Young Jedis taking lessons in the room at #BTGLung2025
Hmmm- the place where tiragolumab will be laid to rest?😉
From a striking Atlantic sunrise over the City that never sleeps to a gorgeous sunset over the Pacific- with great discussions in between about Bridging Gaps in Lung Cancer care Thank you @OncLive @NarjustFlorezMD @lungoncdoc @DrEdKim for a terrific meeting!
We were asked to amplify @lungoncdoc ‘s polling questions- so here u go #lcsm PLS ANSWER HIS QUESTIONS!!! @NarjustFlorezMD
Polling Q4. EGFRm NSCLC Beyond 1L‼️ Should EGFR inhibition be continued beyond progression? #BTGLung2025 @NarjustFlorezMD @DrEdKim @BalazsHalmosMD @LeXiuning @OncLive
Bridging the Gaps in Lung Cancer Great meeting by @NarjustFlorezMD @DrEdKim and online moderation by @lungoncdoc Please help answer the online questions posed by Eric so that we can actually bridge the gap…successfully! #lcsm @OncLive #BTGLung2025
Kicking off @OncLive Bridging the Gaps in Lung Cancer with Small Cell Lung Cancer — @DrRaviSalgia reviews emerging biomarkers driving potential 2L+ therapeutic options for patients with ES-SCLC #BTGLung2025
What a great list of books to choose from this Summer! Along with my little recommendation for: 👇 @KSusztak @kkariko @RohacsTibor
Which books do oncologists say their peers should read this summer? Loved to contribute to this project, alongside amazing colleagues! oncologynewscentral.com/experience/boo…
Which books do oncologists say their peers should read this summer? Loved to contribute to this project! oncologynewscentral.com/experience/boo…
Stop! Please stop everything you are doing right now and read below super-important message from ECOG-ACRIN chairs- Drs. O’Dwyer and Schnall! If we lose public support for pivotal NCI coop group research and it needs to stop- resuscitating it will be very hard or impossible……
Read more from our co-chairs on the importance of protecting public support for biomedical research: bit.ly/3IvxNQD #CancerResearch #ClinicalTrials
Press release, press release! OS-imertinib and chemo are making the oncology Jumbotron today- and with a very hot play on OS they have nothing to hide! With OS being the 🐘in the room and both MARIPOSA and FLAURA2 reaching this key endpoint- the pendulum has clearly swung in…
The Second Life of Jacqui B- a tough essay but one that does deserve a second read! Its concluding sentence might indeed resonate for so, so many!
In a new essay, Mark Earnest, MD, PhD, and Prateeti Khazanie, MD, write that Jacqui’s heart transplant gives her a new lease on life, but when the Covid pandemic arrives, the boundaries of an immunocompromised life in a hostile political climate become painfully clear. Read the…
📢 The updated @ASCO Living Guidelines for NSCLC without a driver alteration are now published in @JCO_ASCO! We reviewed key new data including HARMONI-2, NIPPON, and more. @BalazsHalmosMD @dwightowenmd ascopubs.org/doi/10.1200/JC…
Random sequence of events taking me back… to baklava! Homemade! (Guess that explains the $8 pricetag w Greece🇬🇷/EU tariffs added?) Still worth it! @PGrivasMDPhD @chadinabhan
Boswellia serrata for radiation necrosis It might be abbreviated BS….but looks like maybe it isn’t??😉
Excited to share our experience (largest so far) using Boswellia for radiation necrosis with brain mets. ORR 60%, median duration 14 months. Amazing responses and a game changer for patients, I highly recommend you check it out!!! pubmed.ncbi.nlm.nih.gov/39993542/ redjournal.org/article/S0360-…
Quite sobering to see the OS curves in Impower010 for the ITT population- if one believes there is benefit for TPS>50- then the equation suggests there could be harm for others… In light of negative BR.31 results this just reiterates- if we wish our pts w resectable EGFR/ALK WT…
New 5-year data from #IMpower010 @JCO_ASCO ☑️PD-L1 ≥50%: Strongest benefit – recommend adjuvant atezolizumab. ☑️PD-L1 ≥1%: Meaningful DFS benefit, trending OS benefit – atezo is supported. ☑️PD-L1 negative/unknown: No proven benefit – not routinely recommended.…